Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Revision: 2, Status: Authorised

Understanding vaccines: key scientific terms and platforms

Draft guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information - Revision 1

Draft guideline on predictive biomarker assays in the context of medicinal product lifecycle

EMA workshop on vaccine antigen master files and vaccine platform technology master files, Online, European Medicines Agency, Amsterdam, the Netherlands, from 9 December 2026, 14:00 (CET) to 9 December 2026, 17:00 (CET)

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Yorvipath, palopegteriparatide, Date of authorisation: 17/11/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Date of authorisation: 09/06/2003, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 64, Status: Authorised